US Department of Defense supports an AlgiPharma initiated in vivo wound healing study on OligoG

AlgiPharma has together with Prof. Chandan Sen, at Ohio State University embarked on a study to investigate the effects of OligoG in a unique biofilm infected in vivo wound healing model.

For further information, please contact:
Philip D. Rye R&D Director;

August 2010

AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases

OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.

Read more

For more information contact:
Yngvar P. Berg, CEO;
Astrid Hilde Myrset, Clinical Director;

January 2010